Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.
Cytochrome P450 3A4 (CYP3A4) metabolizes ∼50% of all clinically used drugs. Although CYP3A4 expression varies widely between individuals, the contribution of genetic factors remains uncertain. In this study, we measured allelic CYP3A4 heteronuclear RNA (hnRNA) and mRNA expression in 76 human liver samples heterozygous for at least one of eight marker SNPs and found marked allelic expression imbalance (1.6-6.3-fold) in 10/76 liver samples (13%). This was fully accounted for by an intron 6 SNP (rs35599367, C>T), which also affected mRNA expression in cell culture on minigene transfections. CYP3A4 mRNA level and enzyme activity in livers with CC genotype were 1.7- and 2.5-fold, respectively, greater than in CT and TT carriers. In 235 patients taking stable doses of atorvastatin, simvastatin, or lovastatin for lipid control, carriers of the T allele required significantly lower statin doses (0.2-0.6-fold, P=0.019) than non-T carriers for optimal lipid control. These results indicate that intron 6 SNP rs35599367 markedly affects expression of CYP3A4 and could serve as a biomarker for predicting response to CYP3A4-metabolized drugs.
Wang
D
D
Department of Pharmacology, Program in Pharmacogenomics, School of Biomedical Science, Ohio State University, Columbus, OH 43210, USA. wang.808@osu.edu
Guo
Y
Y
Wrighton
S A
SA
Cooke
G E
GE
Sadee
W
W
D022981:Allelic Imbalance; D051544:Cytochrome P-450 CYP3A / Q000235:genetics* / Q000378:metabolism; D050171:Dyslipidemias / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D006239:Haplotypes; D056945:Hep G2 Cells; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007438:Introns; D008055:Lipids / Q000097:blood; D008099:Liver / Q000201:enzymology*; D016015:Logistic Models; D016017:Odds Ratio; D009820:Ohio; D010597:Pharmacogenetics; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D012332:RNA, Heterogeneous Nuclear / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D014162:Transfection; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D012332:RNA, Heterogeneous Nuclear; D012333:RNA, Messenger; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
Hepatology. 2003 Oct;38(4):978-88
14512885
Clin Pharmacol Ther. 1998 Mar;63(3):332-41
9542477
Curr Drug Metab. 2002 Dec;3(6):561-97
12369887
J Natl Cancer Inst. 1999 Sep 15;91(18):1588-90
10491443
Genes Chromosomes Cancer. 2006 Dec;45(12):1143-54
16977606
Drug Metab Dispos. 2009 Oct;37(10):2112-7
19581388
Pharmacogenetics. 2002 Mar;12(2):121-32
11875366
Clin Pharmacol Ther. 1997 Apr;61(4):410-5
9129558
Pharmacogenetics. 2000 Jul;10(5):373-88
10898107
Am J Cardiol. 2003 Jul 15;92(2):152-60
12860216
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32
15358046
Pharmacogenomics J. 2009 Feb;9(1):49-60
18825162
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
12406645
Biotechniques. 2003 May;34(5):1068-72
12765033
Eur J Clin Pharmacol. 2008 Sep;64(9):877-82
18528690
Blood. 2008 Aug 15;112(4):1013-21
18523153
Nucleic Acids Res. 2000 Jul 15;28(14):2815-22
10908340
J Natl Cancer Inst. 1998 Aug 19;90(16):1225-9
9719084
Clin Gastroenterol Hepatol. 2007 Mar;5(3):388-93
17368239
Clin Pharmacol Ther. 2002 Mar;71(3):196-204
11907494
Pharmacogenomics J. 2009 Oct;9(5):319-26
19506580
Xenobiotica. 2008 Sep;38(9):1240-51
18720283
Pharmacogenomics. 2007 May;8(5):443-53
17465708
Curr Drug Metab. 2005 Aug;6(4):369-83
16101575
Biochem Biophys Res Commun. 1999 May 27;259(1):201-5
10334940
J Clin Pharmacol. 2006 Nov;46(11):1356-69
17050801
Genes Dev. 2002 Mar 1;16(5):594-607
11877379
Nucleic Acids Res. 1988 Feb 11;16(3):1215
3344216
Cancer Res. 2004 Nov 15;64(22):8461-7
15548719
J Pharmacol Exp Ther. 2005 Aug;314(2):626-35
15845858
Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81
19802823
Mol Pharmacol. 2004 Feb;65(2):326-34
14742674
Drug Metab Dispos. 2003 Jun;31(6):755-61
12756208
Clin Chim Acta. 2008 Dec;398(1-2):15-20
18727922
Pharmacol Ther. 2006 Oct;112(1):71-105
16714062
Nat Genet. 2001 Apr;27(4):383-91
11279519
J Biol Chem. 2008 Apr 11;283(15):9674-80
18268015
Clin Pharmacol Ther. 2005 Nov;78(5):551-8
16321621
Am J Hum Genet. 2004 Dec;75(6):1059-69
15492926
J Pharmacol Exp Ther. 1994 Jul;270(1):414-23
8035341
Hum Mol Genet. 2004 Dec 1;13(23):2959-69
15459178
Mol Cell. 2008 Apr 25;30(2):179-89
18439897
J Pharmacol Exp Ther. 2004 Dec;311(3):1088-96
15282265
Pharmacogenomics. 2009 Jun;10(6):1017-24
19530969
Pharmacogenetics. 2004 Aug;14(8):523-5
15284534
Am J Hum Genet. 2008 Jul;83(1):77-88
18597733
Am J Hum Genet. 2004 Jun;74(6):1322-5
15195661
Clin Pharmacol Ther. 1999 Sep;66(3):288-94
10511065
Drug Metab Dispos. 2006 Jan;34(1):131-7
16243958
Pharmacogenet Genomics. 2005 Oct;15(10):693-704
16141795
Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):171-82
16866606
Drug Metab Dispos. 2008 Jan;36(1):169-81
17925385
Pharmacogenetics. 2002 Jul;12(5):355-66
12142725
Annu Rev Pharmacol Toxicol. 2002;42:1-23
11807162
Gene Expr. 2003;11(2):95-104
12837040
BMC Med Genomics. 2008 Jun 11;1:24
18547414
Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305
16171783
Am J Cardiol. 2004 Jan 1;93(1):104-7
14697480